Chapter 25: Two Handwritings
The notebook scan contained two kinds of certainty.
Mine appeared in narrow black letters beside dates, questions, and limitations. I recorded what we observed, what remained unknown, and what would have to be repeated.
The second handwriting appeared in blue across the margins.
Remove hesitation.
Lead with recovery.
Investors need a promise, not a process.
I recognized the wide capital C before anyone said Celeste's name.
Recognition was not proof.
The outside custodian had recovered the scan from a brand archive, not the controlled scientific file. Its metadata showed it was created three weeks before an investor presentation, almost a year after my original notebook pages.
"Could the annotations be yours?" the audit chair asked Celeste.
She studied the screen.
"I reviewed many presentations."
"That is not an answer."
"The writing resembles mine."
It was the first honest sentence she had offered the committee without narrowing it.
Nathan intervened. "Marketing comments on a copy do not alter the scientific record."
"They do if the copy later becomes the source for company history," Rhea said.
The custodian opened the investor deck built from the scan. My caution statements were gone. Celeste's phrases remained, converted into confident declarations about what the platform would one day do.
The deck's approval history showed my name removed from the routing list after I rejected the language. Nathan approved the legal disclaimer on the final slide. Conrad approved release.
Each person could say someone else handled the science.
Together, they sent the promise to investors.
No real treatment names.
No patient details.
Only the transformation of uncertainty into ownership.
I remembered that presentation. I had refused to approve it because the language outran the evidence. Celeste told me privately that scientists confused humility with virtue and expected everyone else to pay for it.
The meeting calendar confirmed I was removed from the investor preparation group the next day.
"Did you add these notes before or after Evelyn rejected the deck?" the audit chair asked.
Celeste looked toward our father.
He did not help her.
"I don't remember."
"Did anyone tell investors Dr. Sterling refused to approve the language?"
"Presentations contain consolidated company positions. They do not list every internal disagreement."
"Did you leave her name on the research slide?"
Celeste did not answer.
The final deck credited the science to Sterling Biotech's Executive Innovation Office—the office she led.
The custodian compared the handwriting with undisputed notes Celeste had written on three board presentations. The same loop appeared in the C. The same capital R began below the line and rose through it.
An examiner would need originals before giving an opinion. The committee recorded the resemblance and no more.
I asked to see the final page.
My original entry described the earliest research as promising but incomplete. The sentence ended with a reminder that public language should preserve uncertainty until independent replication.
Someone had drawn a line through preserve uncertainty.
In blue, the second hand wrote:
Delete before investor copy.
Beneath it appeared a signature-style initial.
C.
Celeste stood.
"This is absurd. You are putting my handwriting on trial because your technical notes were unusable for normal people."
"Your handwriting is not on trial," I said. "The company's authorship story is."
"I made your work understandable."
"You made uncertainty disappear."
"I made the company valuable."
The words entered the record.
My father shifted in his chair. Nathan looked down at the approval history. Celeste had stated their shared principle more directly than either man ever would.
Value first.
Accuracy if it survived.
She realized it a second too late.
The audit chair asked the custodian to preserve the audio and obtain the original annotated copy. Celeste's attorney requested a break.
Before leaving, my sister looked at the black writing and the blue writing sharing one page.
For five years, she had claimed we built the same thing together.
The notebook showed the difference.
I had written what we knew.
She had written what she wanted investors to believe.